The α2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats

@article{Haapalinna2003TheA,
  title={The $\alpha$2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats},
  author={A. Haapalinna and T. Leino and E. Heinonen},
  journal={Naunyn-Schmiedeberg's Archives of Pharmacology},
  year={2003},
  volume={368},
  pages={342-351}
}
The present experiments investigated the effects of the specific α2-adrenoceptor antagonist atipamezole, alone and in combination with a dopamine agonist, on motor function in rats with a unilateral 6-hydroxydopamine lesion of the nigro-striatal pathway and on exploratory behaviour and cardiovascular function in rats equipped with telemetry transmitters. Dexmedetomidine, an α2-adrenoceptor agonist and the α2-adrenoceptor antagonists idazoxan and yohimbine were used as reference compounds. In… Expand
Pharmacological profile of intrathecal fadolmidine, a α2-adrenoceptor agonist, in rodent models
Modulation of l-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus
...
1
2
3
4
...

References

SHOWING 1-10 OF 57 REFERENCES
Specific α2-adrenoreceptor antagonists induce behavioural activation in the rat
...
1
2
3
4
5
...